Skip directly to content

TAGline Spring 2015

Optimism is not without merit, but the science remains incredibly fragile

By Richard Jefferys

We’re pretty optimistic in this 15-year period
we will get those two new tools.

—Bill Gates, World Economic Forum, January 23, 2015

Earlier this year, Bill Gates caused a ripple in the media by expressing optimism that a vaccine and a cure for HIV will become a reality within the next 15 years.

TAGline Spring 2015

We won’t end HIV as an epidemic with anemic goals, delayed surveillance data, feeble support of state policies and resource needs, and an inadequate implementation science agenda

By Kenyon Farrow

The U.S. National HIV/AIDS Strategy (NHAS) ends its five-year run at the end of 2015 with mixed results.

TAGline Spring 2015

Not only is it the right thing to do for the health of New Yorkers, but a new analysis demonstrates that it is also cost-effective

By Ginny Shubert, Housing Works; and Mark Harrington

In June 2014, New York Governor Andrew Cuomo made history by committing New York State to end AIDS as an epidemic by the year 2020. The goal is ambitious, but grounded in reality. NYS has always been a center of innovation in the fight against AIDS and has reduced the number of annual new HIV infections by 40 percent over the last decade while the rest of the nation saw no decline.

TAGline Spring 2015

By Tim Horn

With growing recognition that science and discovery have forged the tools necessary to effectively diagnose, treat, and, indeed, eliminate three of the world’s most lethal infectious diseases—HIV/AIDS, tuberculosis, and hepatitis C—there is a need for greater mobilization and strengthened accountability among all stakeholders.

TAGline Spring 2015

NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS

April 2015

On Targets and Timelines
With growing recognition that science and discovery have forged the tools necessary to effectively diagnose, treat, and, indeed, eliminate three of the world’s most lethal infectious diseases—HIV/AIDS, tuberculosis, and hepatitis C—there is a need for greater mobilization and strengthened accountability among all stakeholders.

Ending the HIV Epidemic (ETE) in NYS

Projected Fiscal Impact of Recommended Expansions of HIV Prevention, Antiretroviral Treatment, and Housing Supports

March 2015

Ending AIDS as an epidemic is not just the right thing to do for the health of New Yorkers – it’s also cost-effective. We simply can’t afford a status-quo approach to HIV. Every new HIV infection costs $443,904 in health spending alone. ETE implementation would improve the health of New Yorkers living with HIV and prevent 10,850 new primary HIV infections between now and 2020 as well as thousands of secondary downstream infections.

Guiding Principles for Eliminating Disease-Specific Criminal Laws

February 27, 2015

1) The Positive Justice Project is dedicated to eliminating disease-specific criminal laws that base liability on an individual’s health status rather than on the intent to harm another individual. We oppose the use of felony laws, and the associated lengthy terms of incarceration that treat health status as evidence of wrongful intent, and transmission of a treatable illness as equivalent to manslaughter, vehicular homicide, and other forms of assaults that pose immediate, lifethreatening harm to another.

2) The Steering Committee of the Positive Justice Project supports

Table 1. Current Clinical Trials

Trial

Trial Registry Identifier(s)

Manufacturer/
Sponsor(s)

Phase

Estimated Study Completion Date

ADOPTIVE IMMUNOTHERAPY

Early ART in combination with autologous HIV-specific cytotoxic T lymphocyte (CTL) infusion

NCT02231281

Yongtao Sun, MD, PhD, Tangdu Hospital, the Fourth Military Medical University

Phase III

December 2016

HXTC: HIV 1 antigen expanded specific T cell therapy

NCT02208167
(not yet open for enrollment)

University of North Carolina, Chapel Hill

Phase I

September 2018

ANTIBODIES

3BNC117 (broadly neutralizing monoclonal antibody)

NCT02018510

Rockefeller University

To:           

Richard Gonzalez, Chairman of the Board, Chief Executive Officer. AbbVie Incorporated
George Hanna Vice President, Virology Development. Bristol-Myers Squibb
Gary Rose, Director Global Medical Advocacy, Virology. Bristol-Myers Squibb
Norbert W. Bischofberger, PhD, Executive Vice President. Gilead Sciences
Daria Hazuda, PhD, Vice President. Merck
Mike Miller. HIV Drug Discovery & Development, Merck
Paul Schaper, Executive Director, Global Health Policy. Merck Sharp & Dohme
David Anderson, MD, Senior Medical Director. Janssen Therapeutics
Frank Tomaka, Senior Director, Global Clinical

Pages